Literature DB >> 25680353

Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.

Stacey B Trooskin1, Joanna Poceta, Caitlin M Towey, Annajane Yolken, Jennifer S Rose, Najia L Luqman, Ta-Wanda L Preston, Philip A Chan, Curt Beckwith, Sophie C Feller, Hwajin Lee, Amy S Nunn.   

Abstract

BACKGROUND: Many of the five million Americans chronically infected with hepatitis C (HCV) are unaware of their infection and are not in care.
OBJECTIVE: We implemented and evaluated HCV screening and linkage-to-care interventions in a community setting.
DESIGN: We developed a comprehensive, community-based HCV screening and linkage-to-care program in a medically underserved neighborhood with high rates of HCV infection in Philadelphia, Pennsylvania. We provided patient navigation services to enroll uninsured patients in insurance programs, facilitate referrals from primary care physicians and link patients to an HCV infectious disease specialist with intention to treat and cure. PATIENTS: Philadelphia residents were recruited through street outreach. MAIN MEASURES: We measured anti-HCV seroprevalence and diagnosis, linkage and retention in care outcomes for chronically infected patients. KEY
RESULTS: We screened 1,301 participants for HCV; anti-HCV seroprevalence was 3.9 % and 2.8% of all patients were chronically infected. Half of chronically infected patients were newly diagnosed; the remaining patients were aware of infection but not in care. We provided confirmatory RNA testing and results, assisted patients with attaining insurance and linked most chronically infected patients to a primary care provider. The biggest barrier to retaining patients in care was obtaining referrals for subspecialty providers; however, we obtained referrals for 64% of chronically infected participants and have retained most in subspecialty HCV care. Several have commenced treatment.
CONCLUSIONS: Non-clinical screening programs with patient navigator services are an effective means to diagnose, link, retain and re-engage patients in HCV care. Eliminating referral requirements for subspecialty care might further enhance retention in care for patients chronically infected with HCV.

Entities:  

Mesh:

Year:  2015        PMID: 25680353      PMCID: PMC4471023          DOI: 10.1007/s11606-015-3209-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  48 in total

1.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

Review 2.  Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles.

Authors:  Gloria Searson; Ellen S Engelson; Damaris Carriero; Donald P Kotler
Journal:  Liver Int       Date:  2014-02-07       Impact factor: 5.828

3.  Does geographic access to primary healthcare influence the detection of hepatitis C?

Authors:  Thomas Astell-Burt; Robin Flowerdew; Paul J Boyle; John F Dillon
Journal:  Soc Sci Med       Date:  2011-03-03       Impact factor: 4.634

Review 4.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

5.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Family physicians' knowledge and screening of chronic hepatitis and liver cancer.

Authors:  Jeanne M Ferrante; Dock G Winston; Ping-Hsin Chen; Andrew N de la Torre
Journal:  Fam Med       Date:  2008-05       Impact factor: 1.756

8.  Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013.

Authors:  Lauren J Stockman; Sheila M Guilfoye; Andrea L Benoit; James M Vergeront; Jeffrey P Davis
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-04-11       Impact factor: 17.586

9.  Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection.

Authors:  Lauren Fusfeld; Jyoti Aggarwal; Carly Dougher; Montserrat Vera-Llonch; Stephen Bubb; Mrudula Donepudi; Thomas F Goss
Journal:  BMC Infect Dis       Date:  2013-05-23       Impact factor: 3.090

10.  Community-based HCV screening: knowledge and attitudes in a high risk urban population.

Authors:  Brianna L Norton; Corrine I Voils; Sarah H Timberlake; Emily J Hecker; Neela D Goswami; Kim M Huffman; Anneka Landgraf; Susanna Naggie; Jason E Stout
Journal:  BMC Infect Dis       Date:  2014-02-10       Impact factor: 3.090

View more
  43 in total

1.  Monitoring the hepatitis C care cascade using administrative claims data.

Authors:  Cheryl Isenhour; Susan Hariri; Claudia Vellozzi
Journal:  Am J Manag Care       Date:  2018-05       Impact factor: 2.229

2.  Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014.

Authors:  Catelyn Coyle; Helena Kwakwa; Kendra Viner
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

3.  Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.

Authors:  Alexander J Millman; Boatemaa Ntiri-Reid; Risha Irvin; Maggie H Kaufmann; Andrew Aronsohn; Jeffrey S Duchin; John D Scott; Claudia Vellozzi
Journal:  Top Antivir Med       Date:  2017 Jul/Aug

4.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

5.  Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net.

Authors:  Mandana Khalili; Robert J Wong
Journal:  Dig Dis Sci       Date:  2018-12       Impact factor: 3.199

Review 6.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 7.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

8.  Dual-Routine HCV/HIV Testing: Seroprevalence and Linkage to Care in Four Community Health Centers in Philadelphia, Pennsylvania.

Authors:  Catelyn Coyle; Helena Kwakwa
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

9.  Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Authors:  Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Mallory O Johnson; Tessa M Napoles; Elise D Riley
Journal:  AIDS Care       Date:  2019-03-04

10.  Evaluation of a recombinant multiepitope antigen for diagnosis of hepatitis C virus: A lower cost alternative for antigen production.

Authors:  Ronaldo Luis Thomasini; Hortencia Gisele Amaro Souza; Oscar Bruna-Romero; Antonio Helvecio Totola; Neiva Sellan Lopes Gonçales; Cristiano Xavier Lima; Mauro Martins Teixeira
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.